TheraRadar
Data updated: May 26, 2026

SUPRENZA (phentermine hydrochloride)

Metabolic Approved 2011-06-13
Jump to: Indications Approvals Trials Competitors Safety Patents
2
Indications
--
Phase 3 Trials
14
Years on Market

Details

Status
Discontinued
First Approved
2011-06-13
Patent Cliff
2029

Pro Metrics

Patent cliff and revenue data

Unlock with Pro
Routes
ORAL
Dosage Forms
TABLET, ORALLY DISINTEGRATING

Companies

CITIUS PHARMS
Active Ingredient: PHENTERMINE HYDROCHLORIDE

SUPRENZA Approval History

2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
24 FDA actions from 2011 to 2014
Feb 2014 SUPPL
Mfg · Manufacturing (CMC)
Jul 2013 SUPPL
Label · Labeling
FDA Letter Label
Jun 2013 SUPPL
Label · Labeling
FDA Letter Label

What SUPRENZA Treats

2 FDA approvals

Originally approved for its first indication in 2011 . Covers 2 distinct patient populations.

  • Other (2)
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
⭐

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

ClinicalTrials.gov ↗ Pro

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

SUPRENZA FDA Label Details

View full patent landscape →
1 OB patents · 1 families · 5 international docs across 3 countries

SUPRENZA Patents & Exclusivity

Latest Patent: Mar 2029

Patents (1 active)

US8440170 Expires Mar 14, 2029
Source: FDA Orange Book

Pro Intelligence Preview

Deep insights for SUPRENZA

Revenue Insights

  • • Quarterly revenue tracking
  • • Historical trend analysis

Patent Timeline

  • • Cliff: 2029
  • • 9 active patents

Trial Analysis

  • • Clinical trial tracking
  • • Development stage analysis

Competitive Landscape

  • • Competitor tracking
  • • Same target/indication analysis
Unlock Full Intelligence

Full approval history • All patents • Revenue trends • Competitor analysis

Data Sources

FDA Approval: NDA202088 → Patents: FDA Orange Book → Trials: ClinicalTrials.gov →

Data sourced from official FDA and NIH databases. Click links to verify on original sources.